scholarly journals Sparse precontrast T 1 mapping for high‐resolution whole‐brain DCE‐MRI

Author(s):  
Zhibo Zhu ◽  
R. Marc Lebel ◽  
Yannick Bliesener ◽  
Jay Acharya ◽  
Richard Frayne ◽  
...  
Keyword(s):  
2016 ◽  
Vol 43 (5) ◽  
pp. 2013-2023 ◽  
Author(s):  
Yi Guo ◽  
R. Marc Lebel ◽  
Yinghua Zhu ◽  
Sajan Goud Lingala ◽  
Mark S. Shiroishi ◽  
...  

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i9-i10
Author(s):  
Michelle Kim ◽  
Hemant Parmar ◽  
Matthew Schipper ◽  
Theresa Devasia ◽  
Madhava Aryal ◽  
...  

Abstract INTRODUCTION: To determine the recommended Phase II dose of RRx-001, a radiosensitizer with vascular normalizing properties, when used with whole-brain radiation therapy (WBRT) for brain metastases, and to assess whether quantitative changes in perfusion MRI after RRx-001 correlate with response. METHODS AND MATERIALS: Five centers participated in this phase I/II trial of RRx-001 given once pre-WBRT then twice weekly during WBRT (30 Gy/10 fractions). Four dose levels were planned (5 mg/m2, 8.4 mg/m2, 16.5 mg/m2, 27.5 mg/m2). Dose-escalation was managed by the Time-to-Event Continual Reassessment Model (TITE-CRM). Correlative DCE-MRI was performed in a subset of patients and linear mixed models used to correlate change in 24-hour T1, Ktrans (capillary permeability) and Vp (plasma volume) with change in tumor volume. RESULTS: Between 2015–2017, 31 patients were enrolled. Two patients dropped out prior to any therapy and 7 were treated with concurrent temozolomide following a study amendment. Median age was 60 years (range, 30–76) and 17 were male. The most common tumor types were melanoma (58%) and non-small cell lung cancer (20%). No dose-limiting toxicities were observed. The most common severe adverse event was grade 3 asthenia in 6.9% (2/29). The median intracranial response rate was 46% (95%CI 24–68) and median overall survival was 5.2 months (95%CI 4.5–9.4). No neurologic deaths occurred. Among 10 evaluable patients undergoing DCE-MRI, a reduction in Vp 24 hours after RRx-001 was associated with reduced tumor volume at 1 month and 4 months (p≤0.01). CONCLUSION: The addition of RRx-001 to WBRT is safe and well-tolerated with favorable intracranial response rates. Because activity was observed across all dose levels, and in the absence of a dose response, the recommended Phase 2 dose is 10 mg administered twice weekly. A reduction in Vp by DCE-MRI 24 hours after RRx-001 suggests anti-angiogenic activity that is associated with longer-term tumor response.


2020 ◽  
Vol 129 ◽  
pp. 109049
Author(s):  
Dinil Sasi S ◽  
Anandh K. Ramaniharan ◽  
Rupsa Bhattacharjee ◽  
Rakesh K. Gupta ◽  
Indrajit Saha ◽  
...  

NeuroImage ◽  
2016 ◽  
Vol 124 ◽  
pp. 32-42 ◽  
Author(s):  
Nick Todd ◽  
Steen Moeller ◽  
Edward J. Auerbach ◽  
Essa Yacoub ◽  
Guillaume Flandin ◽  
...  
Keyword(s):  

2014 ◽  
Vol 27 (11) ◽  
pp. 1387-1396 ◽  
Author(s):  
Marta Vidorreta ◽  
Evelyne Balteau ◽  
Ze Wang ◽  
Enrico De Vita ◽  
María A. Pastor ◽  
...  

2015 ◽  
Vol 36 (8) ◽  
pp. 1444-1449 ◽  
Author(s):  
M.C. Rossi Espagnet ◽  
L. Bangiyev ◽  
M. Haber ◽  
K.T. Block ◽  
J. Babb ◽  
...  

2020 ◽  
Author(s):  
Antoine Klauser ◽  
Bernhard Strasser ◽  
Bijaya Thapa ◽  
Francois Lazeyras ◽  
Ovidiu Andronesi

Low sensitivity MR techniques such as magnetic resonance spectroscopic imaging (MRSI) greatly benefit from the gain in signal-to-noise (SNR) provided by ultra-high field MR. High-resolution and whole-brain slab MRSI remains however very challenging due to lengthy acquisition, low signal, lipid contamination and field inhomogeneity. In this study, we propose an acquisition-reconstruction scheme that combines a 1H-FID-MRSI sequence with compressed sensing acceleration and low-rank modeling with total-generalized-variation constraint to achieve metabolite imaging in two and three dimensions at 7 Tesla. The resulting images and volumes reveal highly detailed distributions that are specific to each metabolite and follow the underlying brain anatomy. The MRSI method was validated in a high-resolution phantom containing fine metabolite structures, and in 3 healthy volunteers. This new application of compressed sensing acceleration paves the way for high-resolution MRSI in clinical setting with acquisition times of 5 min for 2D MRSI at 2.5 mm and of 20 min for 3D MRSI at 3.3 mm isotropic.


2020 ◽  
Author(s):  
Antoine Klauser ◽  
Paul Klauser ◽  
Frédéric Grouiller ◽  
Sebastien Courvoisier ◽  
Francois Lazeyras

There is a growing interest of the neuroscience community to map the distribution of brain metabolites in vivo. Magnetic resonance spectroscopy imaging (MRSI) is often limited by either a poor spatial resolution and/or a long acquisition time which severely limits its applications for clinical or research purposes. We developed a novel acquisition-reconstruction technique combining fast 1H-FID-MRSI sequence accelerated by random k-space undersampling and a low-rank and total-generalized variation (TGV) constrained model. This framework was applied to the brain of four healthy volunteers. Following 20 min acquisition, reconstruction and quantification, the resulting metabolic maps with a 5 mm isotropic resolution reflected the detailed neurochemical composition of all brain regions and revealed part of the underlying brain anatomy. Contrasts and features from the 3D metabolite distributions were in agreement with the literature and consistent across the four subjects. The successful combination of the 3D 1H-FID-MRSI with a constrained reconstruction enables the detailed mapping of metabolite concentrations at high-resolution in the whole brain and with an acquisition time that is compatible with clinical or research settings.


2021 ◽  
Author(s):  
Patrick Vagenknecht ◽  
Maiko Ono ◽  
Artur Luzgin ◽  
Bin Ji ◽  
Makoto Higuchi ◽  
...  

Aim: Abnormal tau accumulation plays an important role in tauopathy diseases such as Alzheimers disease and Frontotemporal dementia. There is a need for high-resolution imaging of tau deposits at the whole brain scale in animal models. Here, we demonstrate non-invasive whole brain imaging of tau-targeted PBB5 probe in P301L model of 4-repeat tau at 130 μm resolution using volumetric multi-spectral optoacoustic tomography (vMSOT). Methods: The binding properties of a panel of imaging probes to amyloid-β, 4-repeat K18 tau fibrils were assessed by using Thioflavin T assay and surface plasmon resonance assay. We identified the probe PBB5 suitable for vMSOT tau imaging. The imaging performance was first evaluated using postmortem human brain tissues from patients with Alzheimers disease, corticobasal degeneration and progressive supranuclear palsy. Concurrent vMSOT and epi-fluorescence imaging of in vivo PBB5 targeting (i.v.) was performed in P301L and non-transgenic littermate mice. Ex vivo measurements on excised brains along with multiphoton microscopy and immunofluorescence staining of tissue sections were performed for validation. The spectrally-unmixed vMSOT data was registered with MRI atlas for volume-of-interest analysis. Results: PBB5 showed specific binding to recombinant K18 tau fibrils, AD brain tissue homogenate by competitive binding against [11C]PBB3 and to tau deposits (AT-8 positive) in post-mortem corticobasal degeneration and progressive supranuclear palsy brain. i.v. administration of PBB5 in P301L mice led to retention of the probe in tau-laden cortex and hippocampus in contrast to wild-type animals, as also confirmed by ex vivo vMSOT, epi-fluorescence and multiphoton microscopy results. Conclusion: vMSOT with PBB5 facilitates novel 3D whole brain imaging of tau in P301L animal model with high-resolution for future mechanistic studies and monitoring of putative treatments targeting tau.


2017 ◽  
Author(s):  
David Grant Colburn Hildebrand ◽  
Marcelo Cicconet ◽  
Russel Miguel Torres ◽  
Woohyuk Choi ◽  
Tran Minh Quan ◽  
...  

Investigating the dense meshwork of wires and synapses that form neuronal circuits is possible with the high resolution of serial-section electron microscopy (ssEM)1. However, the imaging scale required to comprehensively reconstruct axons and dendrites is more than 10 orders of magnitude smaller than the spatial extents occupied by networks of interconnected neurons2—some of which span nearly the entire brain. The difficulties in generating and handling data for relatively large volumes at nanoscale resolution has thus restricted all studies in vertebrates to neuron fragments, thereby hindering investigations of complete circuits. These efforts were transformed by recent advances in computing, sample handling, and imaging techniques1, but examining entire brains at high resolution remains a challenge. Here we present ssEM data for a complete 5.5 days post-fertilisation larval zebrafish brain. Our approach utilizes multiple rounds of targeted imaging at different scales to reduce acquisition time and data management. The resulting dataset can be analysed to reconstruct neuronal processes, allowing us to, for example, survey all the myelinated axons (the projectome). Further, our reconstructions enabled us to investigate the precise projections of neurons and their contralateral counterparts. In particular, we observed that myelinated axons of reticulospinal and lateral line afferent neurons exhibit remarkable bilateral symmetry. Additionally, we found that fasciculated reticulospinal axons maintain the same neighbour relations throughout the extent of their projections. Furthermore, we use the dataset to set the stage for whole-brain comparisons of structure and function by co-registering functional reference atlases and in vivo two-photon fluorescence microscopy data from the same specimen. We provide the complete dataset and reconstructions as an open-access resource for neurobiologists and others interested in the ultrastructure of the larval zebrafish.


Sign in / Sign up

Export Citation Format

Share Document